Company Profile

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.

Employees

2,200

Sector

Pharmaceuticals

More about the company

19/04/24	European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	MT
02/05/23	CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	CI
14/12/22	Court Cancels Public Shares of Vifor Pharma after Merger with CSL	MT
03/11/22	Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	MT
17/10/22	Australia's CSL raises annual profit forecast on Swiss acquisition	RE
12/10/22	Global markets live: Darktrace, Intel, Twitter, Meta, Uber...
12/10/22	Vifor Pharma Gets Approval To Delist From Swiss Bourse	MT
28/09/22	Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	MT
25/08/22	Fitch Pulls Vifor Pharma's Rating After CSL Takeover	MT
23/08/22	Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	MT
22/08/22	Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	MT
18/08/22	UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	MT
17/08/22	Australia biotech giant CSL reports profit dip, flags cost spiral	RE

14/12/21	Octavian Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
14/12/21	Oddo BHF Lifts Price Target on Vifor Pharma, Downgrades Recommendation to Neutral	MT
07/12/21	AlphaValue/Baader Europe Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
01/11/21	Analyst recommendations: Amazon, AMD, Bank of America, Intel, Boeing...
20/09/21	Analyst recommendations: BHP, Lear, Naked Wines, Teradata, Visteon...

14/12/22	Cancellation of remaining publicly held registered shares of Vifor Pharma AG	BU
28/11/22	Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	BU
25/11/22	Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	BU
20/10/22	Approval of extension of exemptions from SIX disclosure and publicity obligations	BU
12/10/22	Approval of delisting of Vifor Pharma AG's registered shares	BU

22/07/24	EU-Kommission verpflichtet Pharmakonzern Vifor zu Gegendarstellung
14/12/22	Vifor: l'action déclarée nulle, décotation le 23 décembre
14/12/22	Vifor-Aktien werden am 23. Dezember dekotiert
28/11/22	CSL Vifor et Fresenius obtiennent le feu vert en Chine pour Ferinject
20/10/22	Vifor toujours exempté de certaines obligations de publier

Date	Insider	Type	Quantity	% Market Cap.
09/03/22	DIRECTOR Swiss Non EXECUTIVE	Sell	8,791	0.0135%
09/03/22	Executive Officer Swiss	Sell	26,274	0.0404%
09/03/22	DIRECTOR Swiss Non EXECUTIVE	Sell	574	0.0009%

Vifor Pharma Share Price

Stocks

VIFN

CH0364749348

Pharmaceuticals

Latest news : Vifor Pharma

Analysts' recommendations: Vifor Pharma

Press Releases: Vifor Pharma

News in other languages: Vifor Pharma

Quotes and Performance

Latest insider transactions

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIFOR PHARMA	+0.48%	+0.36%	-	-	12.27B
ELI LILLY AND COMPANY	+0.84%	-0.94%	+54.61%	+163.31%	1,043B
JOHNSON & JOHNSON	+1.09%	-1.80%	+54.84%	+58.64%	602B
ABBVIE INC.	+0.87%	+3.47%	+34.11%	+90.38%	449B
ROCHE HOLDING AG	+0.78%	-0.71%	+30.04%	+24.61%	327B
NOVARTIS AG	+1.41%	+0.58%	+33.92%	+47.20%	279B
ASTRAZENECA PLC	-0.27%	-1.87%	+22.13%	+23.47%	264B
AMGEN INC.	-1.80%	+0.78%	+22.79%	+60.74%	201B
GILEAD SCIENCES, INC.	-0.81%	+4.46%	+24.65%	+75.04%	169B
PFIZER INC.	-0.18%	+3.85%	+2.12%	-30.01%	143B
Average	+0.18%	-0.68%	+31.02%	+57.04%	386.34B
Weighted average by Cap.	+0.51%	-1.82%	+40.11%	+84.61%